MK-677 Ibutamoren

Origin & Background

The oral GH secretagogue — Merck's most studied

MK-677 (ibutamoren mesylate) was developed by Merck Research Laboratories as an orally active, non-peptide ghrelin receptor agonist. Unlike GHRP peptides which require injection, MK-677 is a small molecule derived from GHRP-6 and spiroindanylpiperidine that can be taken as a once-daily pill. It activates GHS-R1a (the ghrelin receptor) in the hypothalamus and pituitary, stimulating pulsatile GH release without requiring injection.

Merck ran a substantial clinical programme, culminating in the landmark Nass et al. (2008) Annals of Internal Medicine study — a 2-year, double-blind, randomised, placebo-controlled trial of 65 healthy older adults (aged 60-81) at 25mg/day. The results were encouraging: GH and IGF-1 were restored to young-adult levels, fat-free mass increased 1.1kg vs a 0.5kg decline in placebo, and the compound was generally well-tolerated. Development was ultimately discontinued by Merck — not due to safety failures but due to business reasons and the complexity of demonstrating functional benefits beyond biomarker improvement.

Despite non-approval, MK-677 became one of the most widely used "research chemicals" in the GH optimisation community, largely because of its oral convenience, affordable cost, and the availability of legitimate Merck clinical data to cite. It is also one of the most frequently adulterated products in the grey market, with FDA testing revealing hidden ibutamoren in products marketed for other purposes.

Science & Mechanism

Pulsatile GH restoration — without injection

Mechanism of Action

GHS-R1a agonism: MK-677 activates the same ghrelin receptor as the injectable GHRPs — triggering L-type Ca²⁺ channel opening, intracellular calcium increase, and protein kinase C activation → GH pulse release from pituitary somatotrophs.

24-hour GH elevation: The Chapman (1996) study showed 25mg MK-677 increased mean 24-hour GH concentration by 97% and IGF-1 by 88% at 4 weeks. Unlike injectable GHRPs (half-life minutes), the oral bioavailability and extended pharmacokinetics of MK-677 maintain elevated GH throughout the day — a fundamentally different pharmacological profile.

Preservation of pulsatility: Unlike exogenous GH injections (which create a pharmacological bolus and suppress endogenous production), MK-677 amplifies the existing pulsatile GH pattern — increasing peak height without changing peak frequency. This is considered more physiological than continuous GH exposure.

IGF-1 restoration: In older adults with age-related GH decline, MK-677 25mg/day restored IGF-1 to levels normal for young adults (116-358 μg/L range) within weeks. This is the most consistently demonstrated and clinically relevant effect.

Appetite stimulation (orexigenic effect): By activating GHS-R1a in the hypothalamic feeding centres — the same pathway as endogenous ghrelin — MK-677 stimulates appetite. This is a direct pharmacological consequence and is consistently reported in clinical trials. The appetite effect is one of the reasons Merck explored it for sarcopenia and hip fracture recovery, where stimulating appetite is therapeutically desired.

The 12-month Nass 2008 trial results deserve careful reading: FFM +1.1kg (significant), body cell mass +0.8kg (significant), but no improvement in strength or function despite higher FFM. The FFM gain likely contains a substantial intracellular water component rather than purely contractile muscle. Fasting blood glucose increased ~5mg/dL and insulin sensitivity declined — clinically meaningful metabolic signals requiring monitoring. Cortisol increased 47 nmol/L. The hip fracture recovery trial showed improvement in stair-climbing power and gait speed — a functional outcome more clinically compelling than the body composition data.

Community Voices

What people report

Anecdotal ReportNot medical evidence · Research use

"The hunger is real — the first few weeks I was ravenous. That settled down after month two. Sleep quality noticeably better from week one. Muscle fullness and recovery time both improved after 8 weeks. Blood glucose crept up 8 points — I now cycle 8 weeks on, 4 weeks off to manage this."

Male, 47. The three most consistent community observations match the trial data exactly: appetite stimulation (strongest early, habituates), sleep improvement (earliest and most consistent benefit), and mild glucose elevation requiring monitoring. The cyclical approach addresses the insulin resistance concern.

Anecdotal ReportNot medical evidence · Research use

"I use it primarily for sleep. Vivid dreams, deeper sleep, wake up feeling actually rested. The body composition effects I can't confidently attribute given I'm also training and eating well. 12.5mg instead of 25mg seems to give 70% of the benefit with substantially less appetite stimulation."

Female, 39. The lower dose observation is widely shared — 12.5mg is commonly used to reduce the appetite side effect while preserving most GH/IGF-1 benefit. The sleep improvement from enhanced slow-wave GH release is one of MK-677's most reliable subjective effects.

Benefits & Evidence

What the data shows

📈

GH and IGF-1 restoration

Nass 2008 (n=65): restored 24h mean GH and IGF-1 to young-adult range in 60-81yo subjects. Chapman 1996: +97% GH, +88% IGF-1 at 4 weeks (25mg). The most consistently demonstrated and well-quantified effect across all MK-677 trials.

● Strong — multiple Phase 2 RCTs

💪

Fat-free mass preservation

Nass 2008: +1.1kg FFM vs -0.5kg placebo over 12 months in older adults (P<0.001). Hip fracture trial: stair-climbing power and gait speed improved. Note: strength did not improve significantly in the 12-month trial; part of the FFM gain is intracellular water not contractile muscle.

● Moderate — RCT data but functional gains modest

🦴

Bone turnover markers

Bone resorption markers increased 26%, bone formation markers elevated at 8 weeks (obese young males, Wuster study). MK-677 + alendronate mitigated alendronate-induced suppression of bone formation. Bone mineral density effects less consistent across studies.

● Moderate — biomarkers consistent · BMD variable

💤

Sleep quality

GH-coupled slow-wave sleep enhancement. Consistently the most reliably reported subjective benefit by community users. Enhanced REM sleep quality and vivid dreams frequently noted. Underpinned by the same mechanism as GH's natural sleep-promoting effects.

● Moderate — mechanism strong · objective RCT data limited

Safety First

Risks & considerations

Moderate

Insulin resistance and glucose elevation — Nass 2008: fasting glucose +5mg/dL, insulin sensitivity declined. This effect is consistent across trials. Monitor fasting glucose every 4-6 weeks. People with pre-diabetes or metabolic syndrome should use extreme caution.

Moderate

Appetite stimulation — 20-40% of users report significant hunger increase, especially first 4-6 weeks. Can impair weight management goals if not actively managed. Habituation occurs but may not fully resolve.

Moderate

Fluid retention and oedema — lower extremity oedema in 5-10% of users. Mild and typically resolves on discontinuation.

Serious

Potential heart failure risk in susceptible individuals — one Merck trial was stopped early due to congestive heart failure concerns. This risk is likely confined to patients with pre-existing cardiac dysfunction. Contraindicated in anyone with LV dysfunction or cardiac failure history.

Serious

Adulteration risk — FDA 2024 found hidden ibutamoren in products marketed for other purposes. Grey-market MK-677 cannot be verified for purity or dosing accuracy. This is the most practical safety concern for community users.

Synergy Stack

Protecting against the insulin resistance risk

MK-677's insulin resistance risk is its most clinically meaningful concern. The stack is designed to use MK-677's GH benefits while actively counteracting its metabolic liabilities.

💊 Nutrients & Supplements

Berberine

500mg 2-3× daily with meals

Strong evidence

The most evidence-backed OTC AMPK activator and insulin sensitiser. Directly counteracts MK-677's insulin resistance effect. Multiple human RCTs confirm glucose lowering comparable to metformin. Non-negotiable co-intervention for anyone using MK-677 long-term.

Take at night (10pm or later)

Bedtime dosing · fasted ≥2h post-meal

Strong evidence

MK-677's ghrelin-mimetic appetite stimulation is strongest in the daytime hours. Bedtime dosing allows GH release to coincide with natural sleep-related GH pulse while minimising daytime hunger effects. Also aligns elevated GH/IGF-1 with fasted overnight state, maximising lipolytic benefit.

Low dose (12.5mg) trial period

12.5mg for weeks 1-4 · assess then 25mg if tolerated

Moderate evidence

Community evidence and dosing pharmacology both suggest 12.5mg achieves approximately 70% of the IGF-1 benefit of 25mg with substantially less hunger and glucose elevation. Start low to characterise individual response before escalating.

Resistance training

3-4× weekly · essential co-intervention

Strong evidence

The Nass trial showed FFM gains without functional improvements — the IGF-1/GH signal needs a training stimulus to direct muscle protein synthesis toward contractile tissue rather than connective tissue and intracellular water. Without training, MK-677's lean mass benefits are less functional.

⏱ Protocol Notes

Standard protocol: 12.5-25mg nightly, bedtime, fasted ≥2h. 8-12 weeks on, 4 weeks off to monitor glucose response and prevent sustained insulin resistance. Fasting glucose at baseline and every 4 weeks — any sustained increase above 100mg/dL should prompt dose reduction or cessation.

Glucose monitoring is mandatory. The Nass trial documented real insulin resistance at 25mg/day. If you use MK-677, check fasting glucose monthly. Stop or reduce dose if fasting glucose rises above 100mg/dL. People with pre-diabetes, PCOS, or insulin resistance should avoid MK-677.

Honest Assessment

Editor's summary

MK-677 is one of the most uniquely positioned compounds in this book — a Merck-developed drug with substantial legitimate Phase 2 RCT data, sold as a grey-market research chemical because it never reached FDA approval. The clinical data is real: GH/IGF-1 restoration to young-adult levels, fat-free mass preservation, and hip fracture recovery benefits are documented in peer-reviewed trials. The sleep quality benefit is mechanistically solid.

The honest concerns: the insulin resistance signal is real and requires active management. The FFM gains are partly water and do not translate to functional strength without training. One trial was stopped early for heart failure. Long-term safety beyond 2 years is unknown. And the grey market adulteration problem means the product you're actually taking cannot be independently verified.

For someone who genuinely cannot inject, finds injectable GHRPs impractical, and understands the glucose monitoring requirement, MK-677 at 12.5mg bedtime with berberine co-supplementation is a reasonable GH optimisation approach. It is not a replacement for the injectable GH secretagogue protocols — it is a more accessible, less precisely controlled alternative.

Verdict

"Legitimate Merck Phase 2 data, genuinely useful for people who won't inject, real insulin resistance risk requiring active monitoring. Bedtime dosing at 12.5mg with berberine is the most sensible protocol. Not a substitute for injectable GH secretagogues — a more accessible alternative with its own distinct risk profile."